{"id":14688,"date":"2023-08-25T20:57:00","date_gmt":"2023-08-25T12:57:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14688"},"modified":"2024-11-25T00:12:48","modified_gmt":"2024-11-24T16:12:48","slug":"cordavis-launches-first-biosimilar-novartis-hyrimoz-to-compete-with-humira","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14688","title":{"rendered":"Cordavis Launches First Biosimilar: Novartis&#8217; Hyrimoz to Compete with Humira"},"content":{"rendered":"\n<p>Swiss pharmaceutical giant Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) unit Sandoz\u2019s biosimilar product, Hyrimoz (adalimumab), which references AbbVie&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) Humira, has been announced as the first product offered by Cordavis, a newly launched biosimilars-focused subsidiary of US health solutions company CVS Health (<a href=\"https:\/\/www.google.com\/finance\/quote\/CVS:NYSE\">NYSE: CVS<\/a>). The biologic is planned for launch during Q1 2024 under a Cordavis label at a price more than 80% lower than AbbVie\u2019s blockbuster.<\/p>\n\n\n\n<p><strong>Indications and Market Impact<\/strong><br>The injectable drug is indicated for various conditions in the country, including rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u2019s disease (CD), ulcerative colitis (UC), plaque psoriasis, and hidradenitis suppurativa. These indications are no longer covered by the regulatory exclusivity for Humira, opening the market to biosimilar competition.<\/p>\n\n\n\n<p><strong>US Market Entry and Competition<\/strong><br>According to <a href=\"https:\/\/flcube.com\">Fineline Info &amp; Tech<\/a> data, the US patent loss this year has prompted several developers to launch their adalimumab biosimilars to the market. These include Amgen\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/AMGN:NASDAQ\">NASDAQ: AMGN<\/a>) Amjevita, partners Organon (<a href=\"https:\/\/www.google.com\/finance\/quote\/OGN:NYSE\">NYSE: OGN<\/a>) and Samsung Bioepis\u2019s Hadlima, Boehringer Ingelheim\u2019s (BI) Cyltezo, Sandoz\u2019s Hyrimoz, Celltrion\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/068270:KRX\">KRX: 068270<\/a>) Yuflyma, and Biocon\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIOCON:NSE\">NSE: BIOCON<\/a>) Hulio. The entry of these biosimilars is expected to increase competition and potentially reduce costs for patients and healthcare systems.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz\u2019s biosimilar product, Hyrimoz (adalimumab), which references AbbVie&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[234,330,65,587,283,390,225,2316,622,1305,40,912,140,1056,853,865,972,174,24],"class_list":["post-14688","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-abbvie","tag-amgen","tag-auto-immune","tag-bi","tag-biocon-biologics","tag-boehringer-ingelheim","tag-celltrion","tag-cvs-health","tag-gastroenterology","tag-krx-068270","tag-market-launch","tag-nasdaq-amgn","tag-novartis","tag-nse-biocon","tag-nyse-abbv","tag-nyse-nvs","tag-nyse-ogn","tag-organon","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cordavis Launches First Biosimilar: Novartis&#039; Hyrimoz to Compete with Humira - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz\u2019s biosimilar product, Hyrimoz (adalimumab), which references AbbVie&#039;s (NYSE: ABBV) Humira, has been announced as the first product offered by Cordavis, a newly launched biosimilars-focused subsidiary of US health solutions company CVS Health (NYSE: CVS). The biologic is planned for launch during Q1 2024 under a Cordavis label at a price more than 80% lower than AbbVie\u2019s blockbuster.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14688\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cordavis Launches First Biosimilar: Novartis&#039; Hyrimoz to Compete with Humira\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14688\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-25T12:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-24T16:12:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14688#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14688\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cordavis Launches First Biosimilar: Novartis&#8217; Hyrimoz to Compete with Humira\",\"datePublished\":\"2023-08-25T12:57:00+00:00\",\"dateModified\":\"2024-11-24T16:12:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14688\"},\"wordCount\":219,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"Amgen\",\"Auto-immune\",\"BI\",\"Biocon Biologics\",\"Boehringer Ingelheim\",\"Celltrion\",\"CVS Health\",\"Gastroenterology\",\"KRX: 068270\",\"Market launch\",\"NASDAQ: AMGN\",\"Novartis\",\"NSE: BIOCON\",\"NYSE: ABBV\",\"NYSE: NVS\",\"NYSE: OGN\",\"Organon\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14688#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14688\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14688\",\"name\":\"Cordavis Launches First Biosimilar: Novartis' Hyrimoz to Compete with Humira - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-25T12:57:00+00:00\",\"dateModified\":\"2024-11-24T16:12:48+00:00\",\"description\":\"Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz\u2019s biosimilar product, Hyrimoz (adalimumab), which references AbbVie's (NYSE: ABBV) Humira, has been announced as the first product offered by Cordavis, a newly launched biosimilars-focused subsidiary of US health solutions company CVS Health (NYSE: CVS). The biologic is planned for launch during Q1 2024 under a Cordavis label at a price more than 80% lower than AbbVie\u2019s blockbuster.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14688#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14688\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14688#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cordavis Launches First Biosimilar: Novartis&#8217; Hyrimoz to Compete with Humira\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cordavis Launches First Biosimilar: Novartis' Hyrimoz to Compete with Humira - Insight, China&#039;s Pharmaceutical Industry","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz\u2019s biosimilar product, Hyrimoz (adalimumab), which references AbbVie's (NYSE: ABBV) Humira, has been announced as the first product offered by Cordavis, a newly launched biosimilars-focused subsidiary of US health solutions company CVS Health (NYSE: CVS). The biologic is planned for launch during Q1 2024 under a Cordavis label at a price more than 80% lower than AbbVie\u2019s blockbuster.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14688","og_locale":"en_US","og_type":"article","og_title":"Cordavis Launches First Biosimilar: Novartis' Hyrimoz to Compete with Humira","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14688","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-25T12:57:00+00:00","article_modified_time":"2024-11-24T16:12:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14688#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14688"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cordavis Launches First Biosimilar: Novartis&#8217; Hyrimoz to Compete with Humira","datePublished":"2023-08-25T12:57:00+00:00","dateModified":"2024-11-24T16:12:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14688"},"wordCount":219,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","Amgen","Auto-immune","BI","Biocon Biologics","Boehringer Ingelheim","Celltrion","CVS Health","Gastroenterology","KRX: 068270","Market launch","NASDAQ: AMGN","Novartis","NSE: BIOCON","NYSE: ABBV","NYSE: NVS","NYSE: OGN","Organon","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14688#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14688","url":"https:\/\/flcube.com\/?p=14688","name":"Cordavis Launches First Biosimilar: Novartis' Hyrimoz to Compete with Humira - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-25T12:57:00+00:00","dateModified":"2024-11-24T16:12:48+00:00","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz\u2019s biosimilar product, Hyrimoz (adalimumab), which references AbbVie's (NYSE: ABBV) Humira, has been announced as the first product offered by Cordavis, a newly launched biosimilars-focused subsidiary of US health solutions company CVS Health (NYSE: CVS). The biologic is planned for launch during Q1 2024 under a Cordavis label at a price more than 80% lower than AbbVie\u2019s blockbuster.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14688#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14688"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14688#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cordavis Launches First Biosimilar: Novartis&#8217; Hyrimoz to Compete with Humira"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14688"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14688\/revisions"}],"predecessor-version":[{"id":14776,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14688\/revisions\/14776"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}